Catalog No.
DHH72403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q495A1
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MK-7684, CAS: 2231305-30-7
Clone ID
Vibostolimab
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial., PMID:39775043
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies., PMID:39230120
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT., PMID:37799715
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer., PMID:37701986
TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer., PMID:37414394
Anti-TIGIT therapies for solid tumors: a systematic review., PMID:36933320
An Anti-TIGIT Antibody with a PD-1 Inhibitor Shows Promise in Solid Tumors., PMID:34819317
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆., PMID:34800678
For research use only. Not for human or drug use.
